Based on the analysis of the genetic alteration profile of the tumor, there were no preexisting genomic alterations in antigen processing and presentation as well as immune response, such as B2M [27,28], PTEN [29,30], STK11 [31,32,33,34], which might account for de novo resistance to ICI treatment. The gene discussed is PTEN; the disease is neoplasm.